Reviews

Endocrine therapy in metastatic breast cancer: a closer look at the current clinical practice


 

Endocrine therapy is a very effective and well tolerated approach in the treatment of hormone receptor positive metastatic breast cancer. Endocrine therapy has shown comparable results to chemotherapy with regard to survival rates, and therefore, it is recommended in the initial treatment of metastatic breast cancer, except in patients with rapidly progressive disease, where chemotherapy is needed. We have several options of endocrine therapy in first and subsequent lines of treatment in premenopausal and postmenopausal women with metastatic breast cancer, and there has been a great progress in the development of newer agents and combinations.
Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Two heads plus four hands equal safe, shorter bilateral mastectomies
MDedge Hematology and Oncology
Dose-dense breast chemotherapy is also cost dense
MDedge Hematology and Oncology
Positive lumpectomy margin risk rises with breast density
MDedge Hematology and Oncology
Nipple-sparing mastectomy feasible in N+ early breast cancer
MDedge Hematology and Oncology
VIDEO: When to use MRI in breast cancer
MDedge Hematology and Oncology
Race, age, BMI had no impact on pCR rates
MDedge Hematology and Oncology
NIH expands cancer research program to include breast density
MDedge Hematology and Oncology
VIDEO: Immediate breast reconstruction results reassuring in select patients
MDedge Hematology and Oncology
VIDEO: Tomosynthesis soon to be standard of care for breast cancer screening
MDedge Hematology and Oncology
How to fix clinical trial accrual
MDedge Hematology and Oncology